Dosimetry in nuclear medicine therapy.

摘要

Nuclear medicine began its therapy practice even before its diagnostic application with the cure of differentiated thyroid carcinoma with ~(131)I in the 1940s. Rare tumours of the neural crest were treated later with ~(131)I-metaiodobenzilguanidine. In the 90ies, radiopeptides were introduced to fight neu-roendocrine tumours expressing somatostatine receptors. At the same time, a parallel track introduced radioimmunotherapy for targeting several kinds of tumors, ending with the recent (almost) worldwide marketing authorization of ~(90)Y ibritumomab tiuxetan (Zevalin~R) and the FDA approval of ~(131)I tositumom-ab (Bexxar~R) for the treatment of non-Hodgkin's lymphoma. Within the last years, new applications of nuclear medicine loco-regional targeted radiotherapy (TRT) came into practice for the treatment of primary liver diseases or liver metastases; the number of patients treated increased steeply over the last years with the availability of the respective therapeutic agents.